SBP-101 is a small molecule commercialized by Panbela Therapeutics, with a leading Phase III program in Pancreatic Ductal Adenocarcinoma. According to Globaldata, it is involved in 5 clinical trials, of which 2 were completed, 1 is ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of SBP-101’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for SBP-101 is expected to reach an annual total of $31 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

SBP-101 Overview

Ivospemin hydrochloride (SBP-101, SUN-101) is under development for the treatment of metastatic pancreatic ductal adenocarcinoma and recurrent acute or chronic pancreatitis, prostate cancer, pancreatic cancer and ovarian cancer. The drug candidate is an analog of polyamine (PA) and is administered through the subcutaneous route. It acts by targeting DNA synthesis.

It was also under development for colon cancer, breast cancer, lung cancer.

Panbela Therapeutics Overview

Panbela Therapeutics (Panbela), formerly Sun BioPharma Inc is a biopharmaceutical company. It develops disruptive therapeutics for the treatment of pancreatic cancer and pancreatitis. The company’s pipeline products include SBP-101. Its SBP-101 produces superior anti-tumour activity in human cancer cell lines and is used for the treatment of patients with pancreatic ductal adenocarcinoma, and pancreatitis. The company offers clinical trials and drug development services. It partners with institutions, cancer centres universities, and research centres for the development of drugs. Panbela is headquartered in Waconia, Minnesota, the US.

The operating loss of the company was US$10 million in FY2021, compared to an operating loss of US$5.7 million in FY2020. The net loss of the company was US$10.1 million in FY2021, compared to a net loss of US$4.8 million in FY2020.

For a complete picture of SBP-101’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.